Theravance Biopharma Inc. (NASDAQ: TBPH) announced completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE